Which hedge funds own TXG? 10X GENOMICS INC, Q2 2026 13F holders
45 tracked hedge funds disclosed a position in TXG (10X GENOMICS INC) in their Q2 2026 13F filings, worth $536.7m in total. The largest holder by portfolio weight is Blue Water Life Science Advisors, LP at 15.5% of its book. 20 opened a new position this quarter: Anomaly Capital Management, LP, Duquesne Family Office LLC, Samlyn Capital, LLC, Pinnbrook Capital Management LP. 7 exited: Capricorn Fund Managers Ltd, Voloridge Investment Management, LLC, Balyasny Asset Management L.P..
- 45
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 20
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 7
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $172m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $40.3m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $537m
- Combined value Sum of the holders' reported positions in the security.
- 3.6%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Capricorn Fund Managers Ltd | 0.3% | $2.2m |
| Voloridge Investment Management, LLC | 0.04% | $10.6m |
| Balyasny Asset Management L.P. | 0.04% | $21.0m |
| Edgestream Partners, L.P. | 0.04% | $1.2m |
| Schonfeld Strategic Advisors LLC | 0.02% | $2.4m |
| Marshall Wace, LLP | 0.0% | $2.2m |
| Qube Research & Technologies Ltd | 0.0% | $799k |
Ownership over time
Who discovered TXG first? Beta
The run: Q3 2025 → Q3 2026, +673%
| Freshford Capital Management, LLC high conviction | Q4 2025 | – | +6.4 pts |
| Quantedge Capital Pte Ltd | Q4 2025 | – | +4.4 pts |
| Casdin Capital, LLC | Q4 2025 | – | +3.4 pts |
| Exome Asset Management LLC | Q2 2025 | 1.3% | +2.5 pts |
| Lancaster Investment Management | Q3 2025 | 3.1% | – |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.